A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 6, 2013, Pages 753-761

  Bannwarth, Bernard ^a   Kostine, Marie ^a   Poursac, Nicolas ^a  

^a HÔPITAL PELLEGRIN   (France)

Author keywords

DMARDs; Janus kinase inhibitor; Pharmacokinetics; Rheumatoid arthritis; Tofacitinib

Indexed keywords

ADALIMUMAB; KETOCONAZOLE; METHOTREXATE; MIDAZOLAM; RIFAMPICIN; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANEMIA; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; INFECTION RISK; LIVER INJURY; LYMPHOPROLIFERATIVE DISEASE; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PATIENT SELECTION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYTOCHROME P-450 CYP3A; HUMANS; JANUS KINASE 1; JANUS KINASE 3; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES;

EID: 84877847008     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.789500     Document Type: Review

References (35)

1. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373:659-72.
2. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
3. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-39.
4. Bannwarth B, Richez C. Clinical safety of tocilizumab in rheumatoid arthritis. Expert Opin Drug Saf 2011;10:123-31.
5. Yamanaka H, Seto Y, Tanaka E, et al. Management of rheumatoid arthritis: the 2012 perspective. Mod Rheumatol 2013;23:1-7.
6. Vaddi K, Luchi M. JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy. Expert Opin Investig Drugs 2012;21:961-73.
7. Norman P. Selective JAK inhibitor and selective Tyk2 inhibitor patents. Expert Opin Ther Patents 2012;22:1233-49.
8. O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013;368:161-70.
9. Flanagan ME, Blumenkopf TA, Brissette WH, et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem 2010;53:8468-84.
10. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP- 690,550). J Immunol 2011;186:4234-43.
11. Milici AJ, Kudlacz EM, Audoly L, et al. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther 2008;10:R14.
12. LaBranche TP, Jesson MI, Radi ZA, et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum 2012;64:3531-42.
13. Walker JG, Ahern MJ, Coleman M, et al. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis 2006;65:149-56.
14. Maeshima K, Yamaoka K, Kubo S, et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-g and interleukin-17 production by human CD4+ T cells. Arthritis Rheum 2012;64:1790-8.
15. Rosengren S, Corr M, Firestein GS, et al. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis 2012;71:440-7.
16. Tofacitinib for the treatment of rheumatoid arthritis (NDA 203214). Advisory Committee Briefing Document, May 9, 2012. Available from: www.fda. gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ ArthritisAdvisoryCommittee/UCM302960.pdf [Last accessed 22 January 2013].
17. Tofacitinib citrate. Summary review of regulatory action. FDA's Center for Drug Evaluation and Research. Application No. 203214Orig1s000. Available from: http://www.accessdata. fda.gov/drugsatfda-docs/nda/2012/ 203214Orig1s000SumR.pdf [Last accessed 22 January 2013].
18. Lawendy N, Krishnaswami S, Wang R, et al. Effect of CP-690,550, an orally active Janus kinase inhibitor, on renal function in healthy adult volunteers. J Clin Pharmacol 2009;49:423-9.
19. Cohen S, Zwillich SH, Chow V, et al. Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment. Br J Clin Pharmacol 2010;69:143-51.
20. Chow V, Krishnaswami S, Chan G, et al. Pharmacokinetics of CP-690,550, a Janus kinase inhibitor, in subjects with impaired renal function and end-stage renal disease [abstract PII-85]. Clin Pharmacol Ther 2009;85(Suppl 1):S63.
21. Renton KW. Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metabol Toxicol 2005;1:629-40.
22. Gupta P, Alvey C, Wang R, et al. Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data. Br J Clin Pharmacol 2012;74:109-15.
23. Chow V, Ni G, LaBadie G, et al. Open label study to estimate the effect of fluconazole on the pharmacokinetics of a JAK3 antagonist (CP-690,550) in healthy adult subjects [abstract PI-93]. Clin Pharmacol Ther 2008;83(Suppl 1):S36.
24. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis. Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60:1895-905.
25. Coombs JH, Bloom BJ, Breedveld FC, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2010;69:413-16.
26. Tanaka Y, Suzuki M, Nakamura H, et al. Phase II study of tofacitinib (CP- 690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res 2011;63:1150-8.
27. Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012;64:617-29.
28. Kremer JM, Cohen S, Wilkinson BE, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP- 690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012;64:970-81.
29. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507.
30. Van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19.
31. Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013;381:451-60.
32. Lee EB, Fleischmann RM, Hall S, et al. Radiographic, clinical and functional comparison of tofacitinib monotherapy versus methotrexate in methotrexate-naive patients with rheumatoid arthritis [abstract 2486]. Arthritis Rheum 2012;64(Suppl):S1049.
33. van der Heijde D, Landewé RBM, Gruben D. Tofacitinib inhibits radiographic progression in patients with rheumatoid arthritis prone to develop structural damage: a post-hoc analysis of a phase 3 trial [abstract 2546]. Arthritis Rheum 2012;64(Suppl):S1075.
34. Winthrop KL, Valdez H, Mortensen E, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis [abstract 2490]. Arthritis Rheum 2012;64(Suppl):S1051.
35. Fox DA. Kinase inhibition - a new approach to the treatment of rheumatoid arthritis. N Engl J Med 2012;367:565-7.